GM-CSF-armed, replication-competent viruses for cancer.
Monoclonal antibody therapy for cancer has significantly altered the natural history of several common cancers. This success was attained only after many years of failure to understand the technical limitations of antibody therapy. In order to further exploit the immune system, tumor vaccine strategies are an active research focus. Virus based immune agents including GM-CSF armed vectors are among these early efforts. Herpes, adenovirus, and vaccinia based vectors encoding GM-CSF have reported intriguing early clinical trial results that are reviewed here.
Burke
James M
JM
Billings Clinic, Department of Hematology and Oncology, United States. jburke@billingsclinic.org
D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology; D002986:Clinical Trials as Topic; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics / Q000276:immunology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D014780:Viruses / Q000235:genetics / Q000276:immunology
D019496:Cancer Vaccines; D016178:Granulocyte-Macrophage Colony-Stimulating Factor